Discovery of JNJ-42847922, a selective orexin-2 antagonist for the treatment of insomnia disorder

被引：0
|
作者：
Letavic, Michael [1 ]
Bonaventure, Pascal [1 ]
Ly, Kiev [1 ]
Aguilar, Zuleima [2 ]
Aluisio, Leah [1 ]
Carruthers, Nicholas [1 ]
Chaplan, Sandra [2 ]
Dugovic, Christine [1 ]
Halter, Robin [2 ]
Koudriakova, Tatiana [2 ]
Lord, Brian [1 ]
Lovenberg, Timothy [1 ]
Kramer, Michelle [2 ]
Morton, Kirsten [1 ]
Ndifor, Anthony [2 ]
Rizzolio, Michele [2 ]
Shah, Chandra [2 ]
Shelton, Jonathan [1 ]
Shoblock, James [1 ]
Sutton, Steven [1 ]
机构：
[1] Janssen Pharmaceut Co, Neurosci Drug Discovery, San Diego, CA USA
[2] Janssen Pharmaceut Co, San Diego, CA USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2015年 / 249卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
244
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia
    Bonaventure, Pascal
    Shelton, Jonathan
    Yun, Sujin
    Nepomuceno, Diane
    Sutton, Steven
    Aluisio, Leah
    Fraser, Ian
    Lord, Brian
    Shoblock, James
    Welty, Natalie
    Chaplan, Sandra R.
    Aguilar, Zuleima
    Halter, Robin
    Ndifor, Anthony
    Koudriakova, Tatiana
    Rizzolio, Michele
    Letavic, Michael
    Carruthers, Nicholas I.
    Lovenberg, Timothy
    Dugovic, Christine
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 354 (03): : 471 - 482
  • [2] The selective orexin-2 antagonist JNJ-42847922(MIN-202) improves sleep in patients with primary insomnia
    Brooks, S.
    Siebenga, P.
    Zuiker, R.
    Jacobs, G.
    Kezic, I.
    Van Gerven, J.
    Luthringer, R.
    De Boer, P.
    Van der Ark, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S655 - S656
  • [3] ACUTE EFFECTS OF SELTOREXANT, A SELECTIVE OREXIN-2 ANTAGONIST (JNJ-42847922), ON DRIVING AFTER BEDTIME ADMINISTRATION
    Brooks, S.
    Zuiker, R. G. J. A.
    Jacobs, G. E.
    Kezic, I.
    Savitz, A.
    Van der Ark, P. D.
    Van Gerven, J. M. A.
    SLEEP, 2021, 44 : A136 - A136
  • [4] The orexin-2 antagonist JNJ-42847922 (MIN-202) improves sleep in patients with major depressive disorder (MDD) suffering from comorbid insomnia
    Brooks, S.
    Kent, J.
    Jacobs, G.
    Van Amerongen, G.
    Kezic, I.
    Luthringer, R.
    Van der Ark, P.
    Van Gerven, J.
    De Boer, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S408 - S409
  • [5] The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
    Recourt, Kasper
    de Boer, Peter
    Zuiker, Rob
    Luthringer, Remy
    Kent, Justine
    van der Ark, Peter
    Van Hove, Ilse
    van Gerven, Joop
    Jacobs, Gabriel
    van Nueten, Luc
    Drevets, Wayne
    TRANSLATIONAL PSYCHIATRY, 2019, 9 (1)
  • [6] The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
    Kasper Recourt
    Peter de Boer
    Rob Zuiker
    Remy Luthringer
    Justine Kent
    Peter van der Ark
    Ilse Van Hove
    Joop van Gerven
    Gabriel Jacobs
    Luc van Nueten
    Wayne Drevets
    Translational Psychiatry, 9
  • [7] Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects
    van der Ark, Peter D.
    Golor, Georg
    van Nueten, Luc
    Nandy, Partha
    de Boer, Peter
    JOURNAL OF PSYCHOPHARMACOLOGY, 2018, 32 (12) : 1330 - 1340
  • [8] Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
    Kasper Recourt
    Peter de Boer
    Rob Zuiker
    Remy Luthringer
    Justine Kent
    Peter van der Ark
    Ilse Van Hove
    Joop van Gerven
    Gabriel Jacobs
    Luc van Nueten
    Wayne Drevets
    Translational Psychiatry, 9
  • [9] The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder (vol 9, 216, 2019)
    Recourt, Kasper
    de Boer, Peter
    Zuiker, Rob
    Luthringer, Remy
    Kent, Justine
    van der Ark, Peter
    Van Hove, Ilse
    van Gerven, Joop
    Jacobs, Gabriel
    van Nueten, Luc
    Drevets, Wayne
    TRANSLATIONAL PSYCHIATRY, 2019, 9 (1)
  • [10] JNJ-42847922/MIN-202, a selective orexin 2 receptor antagonist, demonstrates beneficial effects on mood and sleep in patients with major depressive disorder
    Recourt, K.
    Van Amerongen, G.
    Jacobs, G.
    Zuiker, R.
    Luthringer, R.
    Van der Ark, P.
    Van Gerven, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S866 - S866
12345